| (19) |
 |
|
(11) |
EP 1 288 217 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
17.09.2003 Bulletin 2003/38 |
| (43) |
Date of publication A2: |
|
05.03.2003 Bulletin 2003/10 |
| (22) |
Date of filing: 15.08.2002 |
|
| (51) |
International Patent Classification (IPC)7: C07F 5/02 |
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
Designated Extension States: |
|
AL LT LV MK RO SI |
| (30) |
Priority: |
27.08.2001 US 315183 P
|
| (71) |
Applicant: Pfizer Products Inc. |
|
Groton, Connecticut 06340 (US) |
|
| (72) |
Inventor: |
|
- Ripin, David Harold Brown, Pfizer Global
Groton, Connecticut 06340 (US)
|
| (74) |
Representative: Sewell, Richard Charles et al |
|
UK Patent Department, Pfizer Limited, Ramsgate Road
Sandwich, Kent CT13 9NJ
Sandwich, Kent CT13 9NJ (GB) |
|
| |
|
| (54) |
Preparation of dialkylpyridylboranes |
(57) The present invention relates to method for the preparation of dialkylpyridylboranes
by reacting a pyridine Grignard reagent with an alkoxydialkylborane or a trialkylborane.
The reaction can be conducted at a temperature ranging from about 0°C to about 40°C.
The pyridine Grignard reagent is preferably prepared
in situ by the reaction of a Grignard reagent (RMgX) and a halopyridine in a suitable solvent,
such as tetrahydrofuran, followed by the addition of an alkoxydialkylborane or a trialkylborane
to form a dialkylpyridylborane.